Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
- Monday, December 5, 2022, 7:12
- PR Newswire
- Add a comment
CARMIEL, Israel and BOSTON, Dec. 5, 2022 /PRNewswire/ – Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant…
About the Author
admin has written 21043 stories on this site.